- https://www.novartis.com/stories/novartis-and-pfizer-join-forces-upend-oncology-dogma
Industry labs find that, contrary to earlier evidence, KRAS-driven tumors are not addicted to autophagy.
- https://www.novartis.com/news/international-womens-day-2020
To celebrate International Women’s Day we explore how an inclusive environment that values unique and curious minds helps everyone be inspired to innovate every day.
- https://www.novartis.com/stories/novartis-cancer-researchers-advance-precision-medicine
Learn how NIBR uses next generation sequencing to transform clinical trials and diagnostics in oncology.
- https://www.novartis.com/stories/novartis-researches-smas-genetic-roots
Spinal muscular atrophy (SMA) is the most common genetic casue of infant and toddler death. NIBR scientists are trying to make a back up gene take up the slack.
- https://www.novartis.com/stories/open-science-demystified
Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.
- https://www.novartis.com/stories/novartis-scientists-target-resistance-threat-malaria
Novartis hopes to prevent, treat and block malaria and is conducting clinical trials to test some promising therapies. Learn more.
- https://www.novartis.com/stories/organic-dealmaker-drug-discovery
New Global Head of Business Development and Licensing for research makes connections naturally, decisions scientifically.
- https://www.novartis.com/stories/open-resources-novartis-help-drive-innovation
With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.
- https://www.novartis.com/news/media-library/victor-bulto
- https://www.novartis.com/about/executive-committee/victor-bulto
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page